Skip to main content


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Full Schedule

Full Schedule

  • Friday, May 15, 2026
  • 7:00 AM - 8:00 AM East Coast USA Time
    Continental Breakfast in Exhibit Hall
  • 8:00 AM - 10:00 AM East Coast USA Time
    Educating your Infectious Diseases and Stewardship Teams Through Creative Methods
  • 8:00 AM - 10:00 AM East Coast USA Time
    Engaging your Instituition in Subtainability Efforts Via Antimicrobial Management
  • 8:00 AM - 10:00 AM East Coast USA Time
    Expanding ID and Stewardships Resources by Mastering Outpatient Billing
  • 8:00 AM - 10:00 AM East Coast USA Time
    What's the Microbiome Gut To To With It? Implementing Pathways for Microbiome Products
  • 9:00 AM - 10:00 AM East Coast USA Time
    SIDP Business Meeting
  • 10:00 AM - 10:30 AM East Coast USA Time
    Break in Exhibit Hall
  • 10:30 AM - 10:45 AM East Coast USA Time
    Welcome and Opening Remarks
  • 10:45 AM - 11:45 AM East Coast USA Time
    Keynote: The Evolution of β-Lactamases: Lessons from the Past, Insights from the Future
  • 11:45 AM - 1:30 PM East Coast USA Time
    Lunch on your own
  • 1:30 PM - 3:00 PM East Coast USA Time
    Plenary #1: CAP Conundrums
    Speaker: Marisa Holubar, MD, MS, FIDSA – Stanford University
    Speaker: Diana Yu, PharmD, MS – OHSU Healthcard
     Credit:
    ACPE UAN:0485-9999-26-010-L01-P (1.0 Contact Hour)
  • 3:00 PM - 3:30 PM East Coast USA Time
    Break in Exhibit Hall
  • 3:30 PM - 5:00 PM East Coast USA Time
    Plenary #2: Clinical Complexities
     Credit:
    ACPE UAN:0485-9999-26-011-L01-P (1.5 Contact Hour)
  • 5:00 PM - 6:30 PM East Coast USA Time
    A BUNDLED STEWARDSHIP INTERVENTION TO IMPROVE CEPHALOSPORIN UTILIZATION IN PREGNANT PATIENTS WITH SEVERE PENICILLIN ALLERGY
  • 5:00 PM - 6:30 PM East Coast USA Time
    A Multi‑Modal National Assessment of Linezolid‑Associated Serotonin Syndrome
  • 5:00 PM - 6:30 PM East Coast USA Time
    A Novel Automated Metric and Dashboard to Quantify Frequency of Antimicrobial Stewardship Interventions Across a Multicampus Health System in New England
  • 5:00 PM - 6:30 PM East Coast USA Time
    A Pooled Performance Analysis of ASTar® Rapid Antimicrobial Susceptibility Testing System from Pseudomonas aeruginosa Positive and Contrived Blood Cultures
  • 5:00 PM - 6:30 PM East Coast USA Time
    A Retrospective Evaluation of Echinocandin Use and Discharge Feasibility
  • 5:00 PM - 6:30 PM East Coast USA Time
    A Retrospective Study on Antibiotic Use in Dental Clinics
  • 5:00 PM - 6:30 PM East Coast USA Time
    Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023
  • 5:00 PM - 6:30 PM East Coast USA Time
    Adverse Effects of Dimorphic Mycoses Treatments: Before vs After IDSA’s Histoplasmosis 2025 Treatment Update.
  • 5:00 PM - 6:30 PM East Coast USA Time
    AI-Assisted ICD-10 Bucketing to Accelerate Antimicrobial Stewardship Surveillance: A CHARM Initiative
  • 5:00 PM - 6:30 PM East Coast USA Time
    Alright, STOP, Collaborate, and Listen - Comparing Duration of Antibiotic Therapy for Gram Negative Bacteremia Between an Academic Medical Center and a Community Teaching Hospital
  • 5:00 PM - 6:30 PM East Coast USA Time
    Amplifying Antimicrobial Action by Exploiting Microbial Machinery
  • 5:00 PM - 6:30 PM East Coast USA Time
    ANALYZING URINARY TRACT INFECTIONS (UTI) AND FLUOROQUINOLONE USE WITH THE COLLABORATION TO HARMONIZE ANTIMICROBIAL REGISTRY MEASURES (CHARM)
  • 5:00 PM - 6:30 PM East Coast USA Time
    Antibiotic Selection and Escalation in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia in Tertiary Community Teaching Hospital: A Retrospective Study
  • 5:00 PM - 6:30 PM East Coast USA Time
    Antibiotic Therapy and Outcomes Associated with Outpatient Dental Infections
  • 5:00 PM - 6:30 PM East Coast USA Time
    Antimicrobial Risk Factors for Surgical Site Infections in Spinal Surgeries
  • 5:00 PM - 6:30 PM East Coast USA Time
    Antimicrobial Stewardship in Sepsis: Optimizing Empiric Antipseudomonal and Anti-Methicillin-Resistant Staphylococcus aureus Therapy
  • 5:00 PM - 6:30 PM East Coast USA Time
    Antimicrobial Stewardship Program Staffing in North America: A Cross-Sectional Study
  • 5:00 PM - 6:30 PM East Coast USA Time
    Assessing the Clinical Outcomes on Micafungin Dosing Strategies in Obesity: A Retrospective Cohort Study
  • 5:00 PM - 6:30 PM East Coast USA Time
    Assessing Treatment Response Against Carbapenem-Resistant Acinetobacter baumannii.
  • 5:00 PM - 6:30 PM East Coast USA Time
    Assessment of Clinically Significant Adverse Events for Daptomycin Outpatient Parenteral Antimicrobial Therapy
  • 5:00 PM - 6:30 PM East Coast USA Time
    Assessment of early clinical impacts caused by the discontinuation of a rapid phenotypic diagnostic for gram-negative bacteremia in a multihospital health system
  • 5:00 PM - 6:30 PM East Coast USA Time
    Assessment of Stenotrophomonas maltophilia treatment strategies and clinical outcomes for bloodstream and respiratory infections across a diverse healthcare system
  • 5:00 PM - 6:30 PM East Coast USA Time
    Attenuation of Ceftazidime/Avibactam Plus Aztreonam but Preservation of Levofloxacin Activity in Pseudomonas aeruginosa–Stenotrophomonas maltophilia Co-culture Models
  • 5:00 PM - 6:30 PM East Coast USA Time
    Aztreonam plus Ceftazidime-Avibactam versus Cefiderocol for Metallo-Beta-Lactamase-Producing Gram-Negative Infections: A Multicenter Real-World Comparison
  • 5:00 PM - 6:30 PM East Coast USA Time
    Aztreonam/Avibactam In Vitro Susceptibility Patterns for Multidrug-Resistant Organisms
  • 5:00 PM - 6:30 PM East Coast USA Time
    Bayesian Dosing Simulator (BDS): A Pharmacokinetic Modeling Tool for Optimized Antibiotic Therapy
  • 5:00 PM - 6:30 PM East Coast USA Time
    Beyond the Label: Real-World Dalbavancin Use in Patients With and Without Reported Intravenous Drug Use
  • 5:00 PM - 6:30 PM East Coast USA Time
    Breaking the Blood-Brain Barrier: Viability of Cefazolin in Meningitis Caused by Methicillin-Susceptible Staphylococcus aureus
  • 5:00 PM - 6:30 PM East Coast USA Time
    Bridging Evidence to Practice: Implementation of Early Oral Antibiotic Transition for Bone and Joint Infections
  • 5:00 PM - 6:30 PM East Coast USA Time
    Broad-Spectrum Parenteral Antibiotic Utilization and Resistance Trends in Hematopoietic Stem Cell Transplant Recipients, 2021–2024
  • 5:00 PM - 6:30 PM East Coast USA Time
    Bugs, Barriers, and Burden: Evaluation of the Correlation Between Antimicrobial Resistance and Social Determinants of Health in Tennessee
  • 5:00 PM - 6:30 PM East Coast USA Time
    Case Series: Description of patients receiving dual long-acting injectable (LAI) antiretroviral therapy (ART) for human immunodeficiency virus (HIV) at a Syracuse, New York Inclusive Health Clinic
  • 5:00 PM - 6:30 PM East Coast USA Time
    Cefepime Cost Avoidance Forged with Therapeutic Drug Monitoring: Economic Stewardship in Practice
  • 5:00 PM - 6:30 PM East Coast USA Time
    Cefepime/Zidebactam: In vivo Assessment of Resistance Selection Using Human-Simulated Regimen in a 3-Day Neutropenic Murine Lung Infection Against Carbapenem-Resistant P. aeruginosa and A. baumannii
  • 5:00 PM - 6:30 PM East Coast USA Time
    Ceftazidime-Avibactam versus MEropenem-vaborbactam for the treatment of bLoodstream infections and pneumonia due to carbapenem-resistant Enterobacterales (CAMEL)
  • 5:00 PM - 6:30 PM East Coast USA Time
    Cephalexin 1000 mg Three Times Daily vs. 500 mg Four Times Daily for the Treatment of Uncomplicated Cellulitis
  • 5:00 PM - 6:30 PM East Coast USA Time
    Characterization of monoclonal antibody VYD2311: molecular structure and in vitro neutralisation profile against recent SARS-CoV-2 variants
  • 5:00 PM - 6:30 PM East Coast USA Time
    Clindamycin Resistance Trends in South Florida: A Regional Stewardship Opportunity Comparing Clindamycin to Alternative Antibiotics
  • 5:00 PM - 6:30 PM East Coast USA Time
    Clinical and Virologic Outcomes of Maribavir versus Conventional Antiviral Therapy
  • 5:00 PM - 6:30 PM East Coast USA Time
    Clinical Outcomes of Adult Patients with Pneumonia or Bacteremia caused by Achromobacter species
  • 5:00 PM - 6:30 PM East Coast USA Time
    Clinical Outcomes with Cefazolin Compared to Broad-Spectrum β-lactams as Targeted Therapy for MSSA Bacteremia
  • 5:00 PM - 6:30 PM East Coast USA Time
    Clinical surveillance software optimizes telehealth outpatient parenteral antimicrobial therapy (Tele-OPAT) workflow for 18 small community hospitals
  • 5:00 PM - 6:30 PM East Coast USA Time
    Clinical utilization of cefepime therapeutic drug monitoring in the perioperative period in lung transplant recipients
  • 5:00 PM - 6:30 PM East Coast USA Time
    Clostridioides difficile Resistance to C. difficile-directed Antibiotics
  • 5:00 PM - 6:30 PM East Coast USA Time
    Comparative Evaluation of Human-Simulated Regimens of Cefepime/Zidebactam and Ceftolozane/Tazobactam in a Neutropenic Murine Thigh Infection Model Caused by Multidrug-Resistant Pseudomonas aeruginosa
  • 5:00 PM - 6:30 PM East Coast USA Time
    Comparative Outcomes of Antifungal Prophylaxis Regimens in Lung Transplant Recipients: A Retrospective Cohort Study
  • 5:00 PM - 6:30 PM East Coast USA Time
    Compatibility Assessment of Cefepime/Zidebactam with Commonly Administered Intravenous Antibiotics for Y-Site Co-administration
  • 5:00 PM - 6:30 PM East Coast USA Time
    Confirmed HSV/VZV Meningitis Outcomes in IV Acyclovir only versus IV Acyclovir & PO Valacyclovir Stepdown
  • 5:00 PM - 6:30 PM East Coast USA Time
    Defining Optimal Sampling Times for Meropenem Therapeutic Drug Monitoring in Clinical Practice
  • 5:00 PM - 6:30 PM East Coast USA Time
    Definitive Intravenous Versus Oral Antimicrobial Therapies for Jaw Osteomyelitis
  • 5:00 PM - 6:30 PM East Coast USA Time
    Delabel and Deliver: Financial and Clinical Outcomes of a Health-System's Pilot PEN-FAST-oriented Delabeling Initiative
  • 5:00 PM - 6:30 PM East Coast USA Time
    Description of Oral Antibiotic Use in Staphylococcus Aureus Bloodstream Infections
  • 5:00 PM - 6:30 PM East Coast USA Time
    Development of a Clinical Risk Score to Guide Empiric Therapy for Stenotrophomonas maltophilia
  • 5:00 PM - 6:30 PM East Coast USA Time
    Direct-from-Sample blAST Assay Detects Antimicrobial Resistance Underrepresented by Isolate-Based Susceptibility Testing
  • 5:00 PM - 6:30 PM East Coast USA Time
    Do not overestimate: real tissue-limited antibiotic penetration for more accurate antibiotic selection than MIC
  • 5:00 PM - 6:30 PM East Coast USA Time
    Does cotton pad collection impact urinary kidney injury biomarker quantification in pediatrics?
  • 5:00 PM - 6:30 PM East Coast USA Time
    Dosing Greener: The Environmental Impact of Metronidazole Interval Optimization
  • 5:00 PM - 6:30 PM East Coast USA Time
    Early IV-to-PO Transition for Gram-negative Bacteremia due to Pseudomonas species or Acinetobacter species
  • 5:00 PM - 6:30 PM East Coast USA Time
    Effect of an Integrated Clinical Pharmacist on the Drivers of Prescriber Burnout in the Infectious Disease Clinic Setting
  • 5:00 PM - 6:30 PM East Coast USA Time
    Efficacy and Safety Outcomes of Fluconazole Dosing for Invasive Candida glabrata Infections
  • 5:00 PM - 6:30 PM East Coast USA Time
    Emergence of Trimethoprim‑Sulfamethoxazole Resistance During Suppressive Therapy for MRSA LVAD Infections: A Systematic Review and Analysis
  • 5:00 PM - 6:30 PM East Coast USA Time
    Enterococcus faecalis endocarditis biofilm characterization and an alternative compound
  • 5:00 PM - 6:30 PM East Coast USA Time
    Environmental and Agricultural Determinants of Human Antibiotic Resistance: Implications for U.S. Stewardship Practice
  • 5:00 PM - 6:30 PM East Coast USA Time
    Environmental Drivers of Antimicrobial Resistance: A Multi‑State Analysis Linking Pesticide Intensity to ESBL, CRE, and MRSA Patterns
  • 5:00 PM - 6:30 PM East Coast USA Time
    Epidemiology and Treatment Patterns Associated with Refractory Herpes Simplex Virus Infection: Insights from EHR-Linked Claims Data
  • 5:00 PM - 6:30 PM East Coast USA Time
    Equity of Oral Antimicrobial Therapy in Hospitalized People with Injection-Drug Use Related Infection Who Elect for Self-directed Discharge: A Mixed-Methods Study with Pilot Intervention
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluating a Vancomycin Stewardship Intervention to Optimize Gram-Positive Coverage in Hospitalized Patients
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluating Karius Plasma Next-Generation Sequencing for Bloodstream Infections: Implications for CLABSI Surveillance
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluating the Effectiveness of Michigan Antibiotic Resistance Reduction Coalition Education Programs in Diverse Middle and High School Students in Michigan
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluating Transitions of Care Process for Patients Discharged on Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs (VA) Healthcare System
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluation & Review of Altered Mental Status Treated as a Symptom of a Urinary Tract Infection
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluation of Adherence to Guidelines for Treatment of Suspected Community-Acquired Bacterial Meningitis
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluation of Antimicrobial Use and Resistance Before and After COVID-19 Pandemic: A 6-Year Retrospective Evaluation
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluation of daptomycin dosing strategies and clinical outcomes using an AUC-based method with Bayesian software at an academic multisite health system
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluation of Formulary Restriction Criteria for Cefiderocol at a Large Academic Medical Center
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluation of Inpatient Community Acquired Pneumonia Antibiotic Selection on Clostridioides difficile Development
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluation of Inpatient Isavuconazole Prescribing Practices at a Community‑Based Cancer Center
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluation of Pneumocystis jirovecii Pneumonia Prophylaxis
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluation of Quality of Care in Community Acquired Pneumonia in Non-Intensive Care Unit Patients at Veterans Affairs – San Diego Healthcare System
  • 5:00 PM - 6:30 PM East Coast USA Time
    Evaluation of Vancomycin Resistant Enterococcus Bloodstream Infection Treatment Strategies
  • 5:00 PM - 6:30 PM East Coast USA Time
    Expanding Focused Pharmacist Interventions Relating to Outpatient Parenteral Antimicrobial Therapy and Complex Outpatient Antibiotic Therapy
  • 5:00 PM - 6:30 PM East Coast USA Time
    Expedited Antimicrobial Choice through Targeted Testing (EXACT): Impact of ePlex BCID on Antimicrobial Therapy Optimization
  • 5:00 PM - 6:30 PM East Coast USA Time
    Factors associated with subtherapeutic cefazolin levels among patients with severe infections
  • 5:00 PM - 6:30 PM East Coast USA Time
    Fluoroquinolones/Sulfamethoxazole-Trimethoprim vs Oral Beta-Lactams in Renal Transplant Pyelonephritis: A Retrospective Cohort Study
  • 5:00 PM - 6:30 PM East Coast USA Time
    Guardians of the Gut: Outcomes of Withholding Anti-Clostridioides difficile Therapy in Colonized Patients Following Microbiology Nudge Implementation
  • 5:00 PM - 6:30 PM East Coast USA Time
    Hospital Admissions for Catheter-Related Bloodstream Infections in Dialysis Patients Without Established Outpatient Dialysis Care: Clinical Burden and Potential Impact of Taurolidine/Heparin
  • 5:00 PM - 6:30 PM East Coast USA Time
    ID’ing the Difference: BCID2 Implementation and its Impact on Definitive Antimicrobial Therapy
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of a Pharmacist Led IV-to-PO Conversion Protocol on Length of Stay and Cost Outcomes
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of a Pharmacist-Drive Methicillin-Resistant Staphylococcus aureus Screen on Vancomycin Therapy in Children
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of an Electronic Health Record alert on the number of BioFire® meningitis/encephalitis panels ordered in a large health system
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of an Indication-Based Urine Culture Order Set on Emergency Department urine culture ordering rates
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of an interdisciplinary workgroup on durations of empiric antibiotic therapy and clinical outcomes for pediatric patients with fever and chemotherapy-induced neutropenia
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of Antibiotic Therapy on Weight in Adult Patients
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact Of Dalbavancin On 90-Day Readmission Rate Across Discharge Dispositions
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of Daptomycin MIC on Treatment Outcomes in Patients with Vancomycin-Resistant Enterococcus Bloodstream Infections
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of Integrating Bedside Nurses into Antimicrobial Stewardship to Optimize UTI Management
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of microbiology reporting changes in treatment of moderate-risk ampC-producing organisms
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of Penicillin Allergy on Surgical Prophylaxis Prescribing and PEN-FAST Scores in Solid Organ Transplant Patients
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of Penicillin-Binding Protein 2a Testing on Antimicrobial Optimization in Staphylococcus aureus Bacteremia
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of Pharmacist Integration on OPAT Outcomes in an Immunocompromised Host Infectious Disease Clinic
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of Pharmacoequity Factors on Outcomes of Extended-Spectrum Beta-Lactamase Infection- Preliminary Results
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of Rapid Blood Culture Identification (BCID2) on Time Targeted Antifungal Therapy in Patients with Fungemia: A Pre/Post Retrospective Evaluation
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of Rapid Phenotypic Antimicrobial Susceptibility Testing on Antimicrobial Therapy in Patients with E. coli and K. pneumoniae Bloodstream Infections
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of Switching Between Fidaxomicin and Vancomycin on Clinical Outcomes in Clostridioides difficile Infection: A Retrospective Cohort Study
  • 5:00 PM - 6:30 PM East Coast USA Time
    Impact of Trimethoprim/Sulfamethoxazole Dosage on Outcomes in Stenotrophomonas maltophilia Infections: A Retrospective Cohort Study
  • 5:00 PM - 6:30 PM East Coast USA Time
    Implementation of a data-driven diabetic foot infection guideline
  • 5:00 PM - 6:30 PM East Coast USA Time
    Implementation of a Novel Risk Factor-based Algorithm for Empiric Gram-Negative Treatment of Pneumonia in the Intensive Care Unit
  • 5:00 PM - 6:30 PM East Coast USA Time
    Implementation of an Infectious Diseases Pharmacy Consult to Improve Recommendation Communication and Workflow Efficiency
  • 5:00 PM - 6:30 PM East Coast USA Time
    In Vitro Evaluation of Drug–Drug Interactions Between Cefepime/Zidebactam and Common Antibiotics and Antifungals
  • 5:00 PM - 6:30 PM East Coast USA Time
    In Vivo Efficacy of a Human-Simulated Regimen of Cefepime/Zidebactam in a Neutropenic Mouse Lung Model of Polymicrobial Infection Caused by Carbapenem-Resistant Gram-Negative Bacteria
  • 5:00 PM - 6:30 PM East Coast USA Time
    Incidence of Community-Acquired Pseudomonas aeruginosa Infections in Solid Organ Transplant Recipients (SOTR) and Evaluation of Potential Risk Factors
  • 5:00 PM - 6:30 PM East Coast USA Time
    Infectious Diseases Resident Collaboration with Care Management to Expedite Discharge for Patients Prescribed High-Risk Intravenous Antimicrobials for Outpatient Administration
  • 5:00 PM - 6:30 PM East Coast USA Time
    Integrative Pharmacodynamic Modeling of Tetracycline Monotherapy and Synergistic Combinations in Stenotrophomonas maltophilia Complex
  • 5:00 PM - 6:30 PM East Coast USA Time
    Intrinsic Activity of Durlobactam Against Metallo-β-lactamase-producing Enterobacterales
  • 5:00 PM - 6:30 PM East Coast USA Time
    Label Liberation: Assessing the Safety of a New Graded Challenge Pathway
  • 5:00 PM - 6:30 PM East Coast USA Time
    Linezolid-Induced Thrombocytopenia in Low-Risk Patients
  • 5:00 PM - 6:30 PM East Coast USA Time
    Low- versus High-Dose Daptomycin for Complicated MRSA Bloodstream Infections
  • 5:00 PM - 6:30 PM East Coast USA Time
    Management and Outcomes of Candidozyma (Candida) auris Fungemia in a Single Health System
  • 5:00 PM - 6:30 PM East Coast USA Time
    Management of Pseudomonas aeruginosa Bacteremia with Borderline Minimum Inhibitory Concentrations
  • 5:00 PM - 6:30 PM East Coast USA Time
    Microbial Cell Memory in Biofilms: A New Frontier for Effective Antibiotic Selection in Hard-to-Treat Drug-Resistant Infections
  • 5:00 PM - 6:30 PM East Coast USA Time
    No admission no problem: ambulatory starts for OPAT
  • 5:00 PM - 6:30 PM East Coast USA Time
    Novel Antibiotic-Bacteriophage Combination Effect against MDR Pseudomonas aeruginosa Biofilm
  • 5:00 PM - 6:30 PM East Coast USA Time
    Opportunities for penicillin allergy assessment and de-labelling among hospitalized patients with infectious diseases consultation
  • 5:00 PM - 6:30 PM East Coast USA Time
    Optimization of Empiric Therapy for UTIs with Urinary Antibiograms Stratified by Patient Specific Factors
  • 5:00 PM - 6:30 PM East Coast USA Time
    Oral Amoxicillin Challenge Protocol in Pediatric Patients with Low-Risk Penicillin Allergies
  • 5:00 PM - 6:30 PM East Coast USA Time
    Oral Antibiotic Therapy Reduces Length of Stay in the Emergency Department
  • 5:00 PM - 6:30 PM East Coast USA Time
    Oral Tebipenem Pivoxil vs IV Imipenem-Cilastatin in Patients with Complicated Urinary Tract Infections or Acute Pyelonephritis: Efficacy and Safety Results from the Phase 3 PIVOT-PO study
  • 5:00 PM - 6:30 PM East Coast USA Time
    Oral transition versus intravenous monotherapy in gram positive bacteremia
  • 5:00 PM - 6:30 PM East Coast USA Time
    Oritavancin Heteroresistance in Persistent VRE Bacteremia
  • 5:00 PM - 6:30 PM East Coast USA Time
    Outcome and experience of 2-drug regimen vs 3-drug regimen pre- and post-transition to Long-Acting Injectable Cabotegravir/Rilpvirine
  • 5:00 PM - 6:30 PM East Coast USA Time
    Outcomes in Patients Treated with Letermovir vs Standard Care for Refractory/Resistant Cytomegalovirus
  • 5:00 PM - 6:30 PM East Coast USA Time
    Outcomes of Early Antibiotic Renal Dose Adjustments in Patients with Septic Shock-Associated Acute Kidney Injury
  • 5:00 PM - 6:30 PM East Coast USA Time
    Outcomes of Twice-Daily Ertapenem in Patients with Hypoalbuminemia at an Academic Medical Center
  • 5:00 PM - 6:30 PM East Coast USA Time
    Outpatient Screening Practices for Human Immunodeficiency Virus, Syphilis, and Trichomonas
  • 5:00 PM - 6:30 PM East Coast USA Time
    Phage-first Therapy Restores Beta-lactam Susceptibility in Extensively Drug-Resistant Pseudomonas aeruginosa
  • 5:00 PM - 6:30 PM East Coast USA Time
    Pharmacist Interventions at Discharge for Outpatient Parenteral Antimicrobial Therapy (OPAT): Predictors and Association with Unscheduled Healthcare Utilization
  • 5:00 PM - 6:30 PM East Coast USA Time
    Pharmacist-led transitions of care intervention to address infectious disease tests pending at discharge (TPAD)
  • 5:00 PM - 6:30 PM East Coast USA Time
    Pharmacokinetics and Safety of MK-8527 in Adults With Moderate or Severe Renal Impairment
  • 5:00 PM - 6:30 PM East Coast USA Time
    Pharmacy Protocol for Intravenous to Oral Anti-Infective Conversions Assessment
  • 5:00 PM - 6:30 PM East Coast USA Time
    Phenotypic ESBL Indication from Positive Blood Cultures Rapid Automated Susceptibility Correlated with blaCTX-M Genotype
  • 5:00 PM - 6:30 PM East Coast USA Time
    Posaconazole-induced pseudohyperaldosteronism: Case report and literature review
  • 5:00 PM - 6:30 PM East Coast USA Time
    Pre-transplant penicillin allergy de-labeling using a pharmacist-led collaborative transplant and antimicrobial stewardship approach
  • 5:00 PM - 6:30 PM East Coast USA Time
    Pritelivir demonstrated superior efficacy vs. investigator’s choice treatment for refractory HSV infections in immunocompromised patients: PRIOH-1, phase 3 safety and efficacy results
  • 5:00 PM - 6:30 PM East Coast USA Time
    Prolonged Infusion of Beta-lactam Antibiotics for Treating Ventriculoperitoneal Shunt-related Central Nervous System Infections in Pediatric Patients: A Case Series
  • 5:00 PM - 6:30 PM East Coast USA Time
    Qualitative Assessment of Antibiotic Prescribing through Physician-Pharmacist Collaboration: A Multicenter Study in Korea
  • 5:00 PM - 6:30 PM East Coast USA Time
    Quantitative proteomic assay for direct quantification of bacteriophage LUZ19 for pharmacokinetic applications
  • 5:00 PM - 6:30 PM East Coast USA Time
    Rates of Secondary Pathogen Positivity after Positive PCR Blood Culture Identification
  • 5:00 PM - 6:30 PM East Coast USA Time
    Real-world assessment of rapid blood culture identification technology on emergency department blood culture callback process
  • 5:00 PM - 6:30 PM East Coast USA Time
    Reducing Time to Actionable Results: A Workflow Redesign for BCID Implementation
  • 5:00 PM - 6:30 PM East Coast USA Time
    Retrospective multicenter evaluation of oral step-down versus intravenous carbapenem treatment of extended-spectrum beta-lactamase producing Escherichia coli urinary tract infections
  • 5:00 PM - 6:30 PM East Coast USA Time
    Retrospective, multicenter evaluation of reflex urine culture criteria and workflow changes in emergency departments across six hospitals and three off-campus sites
  • 5:00 PM - 6:30 PM East Coast USA Time
    Retrospective, multi-hospital evaluation of pneumococcal urinary antigen testing before and after a diagnostic stewardship educational campaign with order set updates
  • 5:00 PM - 6:30 PM East Coast USA Time
    Risk Factors for 4th Generation Cephalosporin-Resistant Enterobacterales Clinical Cultures after Negative Rectal Gram-Negative Surveillance Swabs
  • 5:00 PM - 6:30 PM East Coast USA Time
    Safety and feasibility of extended-course oral linezolid therapy in the outpatient setting: five-year experience of a COpAT program
  • 5:00 PM - 6:30 PM East Coast USA Time
    Safety, Tolerability, Pharmacokinetics, and Immunogenicity in a Phase 1 First-in-human Study with VYD2311, a SARS-CoV-2-directed Monoclonal Antibody
  • 5:00 PM - 6:30 PM East Coast USA Time
    Scientific Poster Session and Cocktail Reception in Exhibit Hall
  • 5:00 PM - 6:30 PM East Coast USA Time
    Seeing DIFFerently: Optimizing Fidaxomicin Use in the VA Northeast Ohio Healthcare System
  • 5:00 PM - 6:30 PM East Coast USA Time
    Short versus Long Durations of Oral Beta-Lactam Therapy for Pyelonephritis Managed in the Outpatient Setting
  • 5:00 PM - 6:30 PM East Coast USA Time
    Short-Course vs Long-Course Antibiotic Therapy for Uncomplicated Gram-Negative Bacteremia in Immunocompromised Patients
  • 5:00 PM - 6:30 PM East Coast USA Time
    Streptococcus pneumoniae Bacteremia Treatment Duration in Hospitalized Patients with Community Acquired Pneumonia
  • 5:00 PM - 6:30 PM East Coast USA Time
    Substance Use Disorder and Risk of Hospitalized Bacterial and Fungal Infection in People Living With HIV
  • 5:00 PM - 6:30 PM East Coast USA Time
    Sustained Virologic Suppression at 1-year Follow-up with Long-Acting Combination of Lenacapavir and Cabotegravir
  • 5:00 PM - 6:30 PM East Coast USA Time
    Switch to DOR/ISL (100/0.25 mg) QD from BIC/FTC/TAF: 96-Week Update from a Blinded Phase 3 Study
  • 5:00 PM - 6:30 PM East Coast USA Time
    T2 to TBD: Impact of T2Candida De-implementation on Empiric Echinocandin Use
  • 5:00 PM - 6:30 PM East Coast USA Time
    Target Attainment of Antimycobacterial TDM
  • 5:00 PM - 6:30 PM East Coast USA Time
    Target redundancy: Harnessing complementary PBP binding profile to evaluate synergy between sulbactam and cefepime/zidebactam against dual carbapenemase-producing A. baumannii
  • 5:00 PM - 6:30 PM East Coast USA Time
    The SPICE Must Flow: Comparing Treatment Failure for Low-Risk AmpC-Producing Organisms
  • 5:00 PM - 6:30 PM East Coast USA Time
    Therapeutic Drug Monitoring in Patients Receiving Linezolid Courses Longer than 14 Days: Uptake, Utility, and Impact
  • 5:00 PM - 6:30 PM East Coast USA Time
    Therapeutic Outcomes of Oral Antibiotics in Methicillin-Resistant Staphylococcus aureus Urinary Tract Infections: A Comparison of Linezolid, Trimethoprim–Sulfamethoxazole, and Doxycycline
  • 5:00 PM - 6:30 PM East Coast USA Time
    Tracking the Antibiotic Utilization for Respiratory Conditions (AXR) using CHARM
  • 5:00 PM - 6:30 PM East Coast USA Time
    Treatment strategies and clinical outcomes for patients with pneumonia and/or bloodstream infection (BSI) due to carbapenem-resistant A. baumannii (CRAB): Early insights from the TUNDRA study
  • 5:00 PM - 6:30 PM East Coast USA Time
    Trends in Mortality of Carbapenem-Resistant Pseudomonas aeruginosa Bloodstream Infections: A 12-Year Retrospective Study
  • 5:00 PM - 6:30 PM East Coast USA Time
    Unlocked PO-tential: Impact of an Oral Switch Guideline for Osteomyelitis
  • 5:00 PM - 6:30 PM East Coast USA Time
    Unplanned Returns: Infection-Related Readmission Causes in Complex Outpatient Antimicrobial Therapy Patients
  • 5:00 PM - 6:30 PM East Coast USA Time
    Vancomycin Loading Doses in 1,505 Pediatric Encounters: Real-World AUC Target Attainment and Nephrotoxicity Outcomes Using Bayesian Dosing Software
  • 5:00 PM - 6:30 PM East Coast USA Time
    When Should We Look Under the Curve? Initial Dosing of Vancomycin Using Bayesian Software vs. Weight-Based Dosing
  • 5:00 PM - 6:30 PM East Coast USA Time
    Woundn’t You Like to Know: Impact of Penicillin Binding Protein 2a Screenings on Staphylococcus aureus Wound Infections
  • 5:00 PM - 6:30 PM East Coast USA Time
    Zidebactam: A Novel β-lactam Enhancer Augmenting Cefepime Pharmacodynamics Against Carbapenemase-Producing, Extensively Drug-Resistant Gram-Negatives